CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery

H. J. Benns, M. Storch, J. A. Falco, F. R. Fisher, F. Tamaki, E. Alves, C. J. Wincott, R. Milne,..

Read More

Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs

Simon R. Green, Susan H. Davis, Sebastian Damerow, Curtis A. Engelhart, Michael Mathieson, Beatriz Baragaña, David A. Robinson, Jevgenia Tamjar,..

Read More

Common and unique features of glycosylation and glycosyltransferases in African trypanosomes

Samuel M. Duncan, Michael A.J. Ferguson. Biochem J (2022) 479 (17): 1743–1758. Abstract Eukaryotic protein glycosylation is mediated by glycosyl- and..

Read More

Genome-scale RNA interference profiling of Trypanosoma brucei cell cycle progression defects.

Catarina A. Marques, Melanie Ridgway, Michele Tinti, Andrew Cassidy & David Horn Nat Commun 13, 5326 (2022). Abstract Trypanosomatids, which..

Read More
View All Publications


Scientific Liaison Manager

Ref: SLSC1137

Salary: £43,414 – £51,805 (Grade 8)

Closing date: 7th November 2022


In collaboration with leading Life Sciences partners globally, the DDU has established a portfolio of innovative drug discovery projects to tackle unmet medical need in diseases such cancer, inflammatory diseases, and neurological diseases. Project goals range from identifying lead series demonstrating disease model proof of concept, through to selection of pre-clinical candidates. In addition, we have co-established a national network of collaborators, including the Universities of Oxford and Birmingham, the Francis Crick Institute and the Medicines Discovery Catapult to consolidate UK capabilities and accelerate impact in the development of new therapeutics for age-related diseases.

The DDU…

Read More